Creyon Bio is excited to be part of the inaugural Decoding Bio Snapshot, sharing our view at the intersection of computation and biology as Creyon, along with the other companies profiled, push the pharma and biotech industry forward. Led by Pablo Lubroth at Hummingbird Ventures and Amee Kapadia at Cantos Ventures, this research project highlights the next generation of bio companies.
At Creyon Bio, we develop better precision medicines faster and at lower cost through molecular engineering of Oligonucleotide-Based Medicines (OBMs) – this includes ASOs, siRNAs, guide RNAs, RNA editing guides, mRNAs, aptamers. Creyon is leveraging the driving forces discussed throughout this report – accessibility of data, AI/ML tools, scale and automation, and a culture shift of multidisciplinary teams – to change how OBM drug development is done.
Creyon has built the most informative dataset that connects biophysical properties of OBMs at a quantum chemistry level with purpose-built datasets of 1000’s of IND-like in vivo studies and hundreds of 1000’s of in vitro and ex vivo experiments, and we have combined this with best-in-class tools for OBM engineering, including AI/ML, data science ops, chemistry, and bioassays.
Our un-siloed team includes biologists, chemists, and physicists with both deep quantitative and data science expertise and management experience in driving inter- and multidisciplinary science and engineering teams; legal, business and financial strategists; and clinical, genomics, and advocacy leaders.
With our data, tools, technologies, and team, Creyon is driving non-clinical costs toward zero and improving the probability of early clinical success by replacing trial-and-error screening with engineering and validation to identify safe and efficacious OBMs.
Creyon is changing the economics, scale and timelines at which new medicines are made to address unmet medical needs for diseases that affect millions, thousands, or even just a few.